Four abstracts related to TMC435, an oral investigational hepatitis C drug, will be presented at the European Association for the Study of the Liver’s 47th annual meeting, pharmaceutical firm Medivir AB announced in a press release today.
Planned presentations at the meeting, scheduled for April 18 to April 22 in Barcelona, Spain, include final virologic and SVR24 results of a phase IIB ASPIRE (C206) study of the drug, which is being developed with Janssen R&D Ireland. In the study, researchers evaluated patients with hepatitis C genotype 1 who had not responded to pegylated interferon/ribavirin treatment. Medivir also will present a comparison of quantitative HCV RNA assays using patients undergoing protease inhibitor-based treatment, and a poster on the lack of photosensitivity potential in TMC435.
Abstracts for the presentations are available on the EASL website.